Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

Protagenic Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK CITY, NY / ACCESS NEWSWIRE / NOVEMBER 13, 2025 / PROTAGENIC THERAPEUTICS INC. (NASDAQ:PTIX), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR STRESS-RELATED NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISORDERS, TODAY ANNOUNCED THE SUCCESSFUL COMPLETION OF ENROLLMENT AND DOSING IN ITS MULTIPLE ASCENDING DOSE (MAD) PHASE 1 STUDY EVALUATING ITS LEAD COMPOUND, KNOWN AS PT00114. THE STUDY, CONDUCTED IN HEALTHY VOLUNTEERS, WAS DESIGNED TO ASSESS THE SAFETY AND TOLERABILITY PROFILE OF PT00114 FOLLOWING MULTIPLE DOSES OVER TIME.

Protagenic Therapeutics, Inc.

PTIX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Protagenic Therapeutics, Inc.

PTIX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PTIX